Xolair Gets FDA Approval for Food Allergy Treatment
August 15, 2018
Source: FiercePharma
867
Xolair of Novartis and Roche has been declared as a breakthrough therapy for food allergies including eggs, milk and peanuts by the Food and Drugs Administration (FDA).
The prevalence of food allergies is increasing day by day and could be life-threatening. It affects around 8% of children and 4% of adults in the U.S. To date, there are no FDA-approved treatments.
Xolair was initially used to treat allergic asthma where it met various rivals such as Teva’s Cinqair, GlaxoSmithKline’s Nucala, and AstraZeneca’s Fasenra, all with FDA approval to treat severe eosinophilic asthma.
Till now these drugmakers have been working continuously to include additional indications for their medicines, but none were working on food allergies. However, Sanofi was testing its novel Regeneron-partnered atopic dermatitis drug named Dupixent in order to treat peanut allergies.
Xolair received FDA approval recently for the treatment of chronic idiopathic urticaria, otherwise termed as chronic hives. This positive news helped the drug reprobate in $1.75 billion in the U.S. on last year.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- AZ’s Farxiga Gets FDA Priority Review For Heart Failure January 8, 2020
- Global Recall of CyPass Micro-Stent by Alcon September 3, 2018
- Breakthrough Device Designation Granted to Digital Intervention for Alzheimer’s August 27, 2018
- FDA Approved Eye Drop Oxervate to Treat Neurotrophic Keratitis August 27, 2018
- Experimental Ebola Treatments Approved by Congo as it Sees Flare-Up in Cases August 24, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
